America’s synthetic opioid detection systems are failing to identify the substances actually killing people. Outdated toxicology panels miss nitazenes and other novel compounds, leaving policymakers chasing yesterday’s drug supply whilst manufacturers stay one step ahead. The result? A national blind spot that obscures the true scale and nature of the overdose crisis.

Tennessee data illustrates the problem starkly. Knox County appears as the hotspot for emerging synthetic opioid detection, particularly nitazenes, compounds estimated 10 to 40 times stronger than fentanyl. Yet Chris Thomas, Chief Administrative Officer at the Knox County Regional Forensic Center, reveals uncomfortable truth: “It’s not that Knox County is definitely the hardest-hit spot of the epidemic. Other counties simply don’t have the resources to test for drugs like nitazenes or other novel synthetics. They only have the funding to run basic panels.”

The overdose map reflects where synthetic opioid detection happens, not necessarily where people die. This chilling insight exposes how inadequate forensic capacity distorts understanding of the crisis itself.

Yesterday’s Tests for Tomorrow’s Drugs

Much of America still relies on toxicology panels built for yesterday’s drug supply. These panels reliably identify heroin, oxycodone and fentanyl. They fail at synthetic opioid detection for nitazenes, brorphine and other new synthetic analogues. This gap means policymakers and public health professionals chase outdated trends.

Meanwhile, drug manufacturers exploit loopholes. They evade detection. They remain a step ahead. This pattern repeated with xylazine, the veterinarian tranquiliser that doesn’t respond to naloxone. It took years and too many deaths before xylazine testing became relatively common practice.

Statistics may look highly granular, broken down by county, substance and year. Yet they remain vulnerable to major blind spots. A person who dies with both cocaine and a nitazene in their system might be coded as a “cocaine death” if synthetic opioid detection missed the nitazene. As fentanyl deaths steeply decline, national figures make cocaine seem responsible for a growing share of overdoses. That’s misleading if many cases actually involve cocaine combined with nitazenes or other synthetic opioids that weren’t detected.

Without true grasp of epidemiology, understanding where the epidemic is heading becomes impossible. Stopping it becomes equally impossible.

Budget Structures Block Progress

Medical examiner and coroner offices were created to serve the criminal justice system. They determine cause and manner of death for legal and administrative purposes. Counties or municipalities set their budgets, not health departments. These budgets aren’t structured to empower tracking of emerging drug threats, including synthetic opioid detection.

Detecting nitazenes and other novel compounds requires expensive technology. Liquid chromatography. Gas chromatography. Mass spectrometry. Highly trained personnel who can find these drugs despite their low molecular weight. Many offices, especially in rural areas, lack both infrastructure and funding.

The Drug Enforcement Administration partnered with the University of California San Diego in a promising endeavour to cover costs of secondary laboratory testing. The scale remains minuscule. In the fourth quarter of 2024, the programme received and analysed only 88 samples from 18 states and one US territory. Even the act of saving, storing, recording, packaging and shipping samples requires time and staff that many offices don’t have.

The result is a fragmented, inequitable national surveillance system. The drugs detected depend largely on where a person dies. This lack of understanding paralyses ability to get in front of the supply. Synthetic opioid detection becomes a postcode lottery rather than a public health imperative.

The Money Already Exists

More than 50 billion dollars in opioid abatement settlements now flows to states. Pharmaceutical companies, distributors and pharmacies paid these funds. They were designed to prevent and mitigate further harm from the opioid epidemic. Each state divides its share differently among agencies, counties and community programmes.

This month, a new deal with Purdue Pharma and the Sackler family added up to 7.4 billion dollars in potential additional payments. A portion will reach state and local governments.

Most funds go toward treatment, prevention and harm reduction. All essential work. But little supports forensic and toxicology systems, even though they underpin understanding of the crisis itself. These offices are often so chronically underfunded that even modest investment could be transformational. Improved synthetic opioid detection would help communities respond before the next wave hits.

Many states retain a state-controlled portion of settlements that allows strategic, discretionary use. These funds can have flexible applications. Tennessee recently directed its discretionary share to launch a wastewater drug-testing pilot.

Federal Mandate Could Transform Capacity

Federal policymakers could mandate states to dedicate a small portion of discretionary funds to strengthen forensic capacity nationwide. With this funding, states could broaden toxicology panels to detect novel synthetic opioids and other emerging threats. They could hire and retain forensic toxicologists to interpret results and update testing libraries. They could support staffing and logistics to send samples to DEA or university reference labs for secondary testing. They could integrate death-investigation data with public health systems in real time.

This approach would address the synthetic opioid detection crisis systematically. Currently, offices that lack capacity to test for emerging substances cannot contribute to national understanding of evolving drug supplies. Their deaths get coded to known substances. The actual killers remain invisible in statistics.

Consider the public health implications. When nitazenes first appeared in drug supplies, most jurisdictions couldn’t detect them. Early deaths were attributed to heroin or fentanyl overdoses. By the time synthetic opioid detection capabilities caught up, the compounds had spread widely. Response efforts lagged behind distribution patterns because surveillance systems couldn’t see what was happening.

Breaking the Cycle of Reactive Response

The pattern repeats with each new synthetic variant. Manufacturers create novel compounds that existing tests can’t detect. These substances circulate undetected. Deaths occur. Eventually, forensic laboratories develop new testing protocols. Synthetic opioid detection finally identifies the threat. Public health responses begin. But by then, manufacturers have moved to the next variant.

Comprehensive toxicology would break this cycle. It would let authorities anticipate the next crisis instead of chasing the last. Testing the drug supply is not just a courtroom or administrative function. It’s a cornerstone of public health and effective synthetic opioid detection.

Rural areas face particular vulnerability. Urban centres often have better-resourced medical examiner offices. They can invest in advanced testing technology. They can hire specialised staff. Rural and small-town offices struggle with basic operations. The gap in synthetic opioid detection capacity means rural overdose deaths are most likely to be miscoded.

This creates perverse incentives. Areas hardest hit by the overdose crisis often have least capacity to understand what’s killing their residents. Without accurate data, they can’t make compelling cases for resources. The cycle perpetuates itself.

The Stakes of Staying Blind

Communities can’t solve what they can’t measure. Opioid abatement funds should help. Comprehensive synthetic opioid detection would provide clear picture of the crisis. It would reveal which substances are spreading. It would identify geographic patterns. It would enable targeted interventions before problems become catastrophic.

The technology exists. The expertise exists. The funding exists. What’s missing is the political will to prioritise forensic capacity as public health infrastructure. Medical examiner and coroner offices need recognition as essential components of crisis response, not merely administrative necessities.

Every miscoded death represents a missed opportunity. Missed opportunity to warn communities. Missed opportunity to adjust treatment protocols. Missed opportunity to target prevention efforts. Missed opportunity to disrupt supply chains before they become established.

Strengthening synthetic opioid detection nationwide would transform understanding of the overdose crisis. It would reveal the true scope of emerging threats. It would enable evidence-based responses. It would save lives by ensuring resources target actual problems rather than statistical artefacts created by inadequate testing.

The choice is clear. Invest modestly in forensic capacity now, or continue flying blind whilst the crisis evolves unchecked. The opioid abatement settlements provide the means. The only question is whether policymakers will recognise synthetic opioid detection as the public health priority it demonstrably is.

Source: Time